Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock Holdings Reduced by Trexquant Investment LP

Trexquant Investment LP lowered its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLLFree Report) by 28.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 94,577 shares of the specialty pharmaceutical company’s stock after selling 38,402 shares during the quarter. Trexquant Investment LP’s holdings in Collegium Pharmaceutical were worth $2,911,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Dimensional Fund Advisors LP increased its stake in shares of Collegium Pharmaceutical by 2.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,039,218 shares of the specialty pharmaceutical company’s stock worth $31,987,000 after purchasing an additional 29,529 shares during the last quarter. Jump Financial LLC purchased a new position in Collegium Pharmaceutical during the 4th quarter valued at about $1,179,000. Johnson Investment Counsel Inc. purchased a new stake in Collegium Pharmaceutical during the 4th quarter worth approximately $257,000. BNP Paribas Financial Markets increased its holdings in Collegium Pharmaceutical by 119.6% in the 4th quarter. BNP Paribas Financial Markets now owns 146,543 shares of the specialty pharmaceutical company’s stock worth $4,511,000 after acquiring an additional 79,823 shares in the last quarter. Finally, Versor Investments LP increased its position in shares of Collegium Pharmaceutical by 14.2% during the fourth quarter. Versor Investments LP now owns 10,579 shares of the specialty pharmaceutical company’s stock valued at $326,000 after acquiring an additional 1,316 shares during the last quarter.

Analysts Set New Price Targets

Several analysts have issued reports on COLL shares. Truist Financial upped their price target on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a report on Monday, February 26th. Needham & Company LLC cut Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Friday, May 10th. Piper Sandler downgraded Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 price target for the company. in a research report on Friday, May 10th. Finally, downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 1st. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $39.00.

Check Out Our Latest Research Report on Collegium Pharmaceutical

Collegium Pharmaceutical Stock Performance

COLL stock traded up $0.43 during midday trading on Friday, reaching $34.25. The stock had a trading volume of 320,990 shares, compared to its average volume of 506,732. Collegium Pharmaceutical, Inc. has a 52-week low of $20.83 and a 52-week high of $40.95. The company has a debt-to-equity ratio of 1.98, a quick ratio of 1.14 and a current ratio of 1.21. The stock has a market cap of $1.12 billion, a PE ratio of 14.27 and a beta of 1.06. The firm has a fifty day simple moving average of $36.74 and a two-hundred day simple moving average of $33.11.

Collegium Pharmaceutical (NASDAQ:COLLGet Free Report) last announced its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.25. The business had revenue of $149.75 million during the quarter, compared to the consensus estimate of $147.66 million. Collegium Pharmaceutical had a net margin of 16.46% and a return on equity of 104.98%. As a group, equities research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.63 EPS for the current year.

Insider Transactions at Collegium Pharmaceutical

In other news, Director Garen G. Bohlin sold 28,985 shares of the business’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $32.30, for a total value of $936,215.50. Following the completion of the sale, the director now owns 44,775 shares of the company’s stock, valued at approximately $1,446,232.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 3.98% of the company’s stock.

About Collegium Pharmaceutical

(Free Report)

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Featured Articles

Want to see what other hedge funds are holding COLL? Visit to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLLFree Report).

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with's FREE daily email newsletter.